CRINETICS PHARMACEUTICALS IN
CRNXNASDAQTrading Snapshot
- Day Range
- $84.04 – $85.40
- 52-Week Range
- $32.30 – $85.01
- Volume
- $2.32B
- Avg Volume
- $2.14B
- Shares Outstanding
- 105.8M
- Next Earnings
- Nov 27, 2026
Fundamentals Snapshot
- Annual Revenue
- $8M
- Last Q Revenue
- $25M
- P/E Ratio
- —
- P/S Ratio
- 213.8x
- EPS (TTM)
- $-5.05
- Dividend Yield
- —
- Dilution (1yr)
- +2.8%
Why Investors Own CRNX
- ✓High-growth profile — revenue up +48.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 36% gross margin and 13% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
CRINETICS PHARMACEUTICALS IN
CRNX
StockOtter · stockotter.spaceAbout CRINETICS PHARMACEUTICALS IN
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Financial Comparison: Crinetics Pharmaceuticals (NASDAQ:CRNX) and Lyra Therapeutics (OTCMKTS:LYRA)
Crinetics Pharmaceuticals (NASDAQ: CRNX - Get Free Report) and Lyra Therapeutics (OTCMKTS:LYRA - Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based
Which Healthcare ETF Is the Better Buy: Fidelity's Broad FHLC or State Street's Pharma-Focused XPH?
FHLC captures the whole healthcare opportunity at rock-bottom cost. XPH narrows the bet to pharmaceuticals and charges significantly more for it.
Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the successful completion of the acquisition of Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company
BlackRock Inc. Purchases New Position in Crinetics Pharmaceuticals, Inc. $CRNX
BlackRock Inc. purchased a new position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commissio
AWM Investment Company Inc. Invests $3.18 Million in Crinetics Pharmaceuticals, Inc. $CRNX
AWM Investment Company Inc. bought a new position in Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund boug
Deutsche Bank AG Invests $10.62 Million in Crinetics Pharmaceuticals, Inc. $CRNX
Deutsche Bank AG purchased a new stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchase